New technology will be in place from January 31 to monitor advertisements on social media relating to the promotion of prescription-only medicines (POMs) such as botulinum toxin.
Global pharmaceutical company Allergan has announced key future growth drivers for its medical aesthetics portfolio at its first ever Medical Aesthetics Analyst Day this month.
A clinical study conducted by global pharmaceutical company Allergan suggests that higher doses of Botox Cosmetic (onabotulinumtoxinA) to treat moderate to severe glabella lines produces greater duration of treatment effect.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the marketing authorisation application for Evolus’ botulinum toxin type A formulation.
The results of two studies conducted by pharmaceutical company Galderma (UK) Limited have demonstrated high patient satisfaction for the use of Azzalure (AbobotulinumtoxinA), its botulinum toxin type A product, in the glabellar complex.
US-based medical aesthetic company Evolus Inc has begun a consumer campaign in the US called ‘#NEWTOX NOW’ in the hope to encourage patients to use its botulinum toxin.
Global pharmaceutical company Allergan has received approval from the US Food and Drug Administration (FDA) to market the Natrelle Inspira Cohesive breast implants
Evidence for the inquiry into non-surgical cosmetic procedures in the UK must be submitted to the All-Party Parliamentary Group on Beauty, Aesthetics and Wellbeing (APPG BAW) by July 17.
Healthcare Improvement Scotland (HIS) has confirmed in a Stakeholder meeting earlier this week that aesthetic nurses who own HIS-registered clinics can now legally stock prescription only medications (POMs) such as botulinum toxin and hyaluronidase on premises.
Xeomin® has received cosmetic approval from the US Food and Drug Administration (FDA) for the temporary improvement in the appearance of moderate to severe glabellar lines, or frown lines between the eyebrows, in adult patients.